Czech version of the Edinburgh Cognitive and Behavioral Amyotrophic Lateral Sclerosis Screen – a pilot study

Czech version

Authors: O. Bezdíček; L. Marková; N. Soósová; M. Forgáč
Authors‘ workplace: Laboratoř neuropsychologie J. Diamanta a Elektromyografická laboratoř Neurologická klinika a Centrum klinických neurověd 1. LF UK a VFN v Praze
Published in: Cesk Slov Neurol N 2018; 81(2): 208-212
Category: Short Communication
doi: https://doi.org/10.14735/amcsnn2018208

Overview

Objective:
Our objective was to determine the cutoffs of the Czech version of the Edinburgh Cognitive and Behavioral ALS Screen (ECAS) for the assessment of cognitive impairment in amyotrophic lateral sclerosis (ALS).

Introduction:
ECAS is currently the most specific multi- domain cognitive screening instrument for the detection of cognitive impairment in ALS. It consists of the cognitive and behavioral part and attenuates the interference of motor impairment on cognition during the assessment of patients with ALS. Currently, there are no validated Czech version methods available for the detection of cognitive impairment in ALS.

Methods:
Fifteen ALS patients (age 62.53 ± 11.28 years) and 15 (61.07 ± 10.99 years) age- , gender- and education- matched healthy controls were recruited. The conditional probability of the presence/ absence of cognitive impairment was based on the Mattis Dementia Rating Scale, Second Edition. Subsequently, we performed a psychometric analysis regarding discriminative validity and the detection potential of ECAS based on the receiver operating curve analysis.

Results:
ECAS total score significantly differentiates between ALS and paired controls (p < 0.001) and the scale has a high potential for the detection of cognitive impairment in ALS (area under curve = 83%). The cutoff for the detection of cognitive impairment in ALS was 107/ 136 with 92% sensitivity and 83% specificity.

Conclusion:
We performed a translation and back- translation of ECAS into Czech and showed and showed adequate measurement properties of the Czech version on a sample of patients with ALS and paired controls from the Czech population. ECAS Czech version can be recommended for its detection potential of cognitive impairment in ALS for use in clinical practice.

Key words:
validity – cognitive impairment – amyotrophic lateral sclerosis – Edinburgh Cognitive and Behavioral Amyotrophic Lateral Sclerosis Screen

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.

Sources

1. Robberecht W, Philips T. The changing scene of amyotrophic lateral sclerosis. Nat Rev Neurosci 2013; 14(4): 248– 264. doi: 10.1038/ nrn3430.

2. Baumgartner D. ALS jako TDP43- proteinopatie: kognitivní poruchy u ALS, ALS Plus. Neurol praxi 2016; 17(6): 366– 369.

3. Ringholz GM, Appel SH, Bradshaw M et al. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology 2005; 65(4): 586– 590. doi: 10.1212/ 01.wnl.0000172911.39167.b6.

4. Phukan J, Elamin M, Bede P et al. The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population- based study. J Neurol Neurosurg Psychiatry 2012; 83(1): 102– 108. doi: 10.1136/ jnnp- 2011- 300188.

5. Brooks BR, Miller RG, Swash M et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1(5): 293– 299.

6. Elamin M, Bede P, Byrne S et al. Cognitive changes predict functional decline in ALS: a population-based longitudinal study. Neurology 2013; 80(17): 1590– 1597. doi: 10.1212/ WNL.0b013e31828f18ac.

7. Oh SI, Park A, Kim HJ et al. Spectrum of cognitive impairment in Korean ALS patients without known genetic mutations. PloS One 2014; 9(2): e87163. doi: 10.1371/ journal.pone.0087163.

8. Murphy J, Factor- Litvak P, Goetz R et al. Cognitive- behavioral screening reveals prevalent impairment in a large multicenter ALS cohort. Neurology 2016; 86(9): 813– 820. doi: 10.1212/ wnl.0000000000002305.

9. Raaphorst J, Beeldman E, Schmand B et al. The ALS-FTD- Q: a new screening tool for behavioral disturbances in ALS. Neurology 2012; 79(13): 1377– 1383. doi: 10.1212/ WNL.0b013e31826c1aa1.

10. Baumgartner D, Marusic P, Mazanec R. Stem cell therapy for amyotrophic lateral sclerosis – an overview of current clinical experience. Cesk Slov Neurol N 2017; 80(1): 27– 33. doi: 10.14735/ amcsnn201727.

11. Elamin M, Bede P, Montuschi A et al. Predicting prognosis in amyotrophic lateral sclerosis: a simple algorithm. J Neurol 2015; 262(6): 1447– 1454. doi: 10.1007/ s00415- 015- 7731- 6.

12. Bezdicek O, Ruzicka F, Fendrych Mazancova A et al. Frontal assessment battery in Parkinson‘s disease: validity and morphological correlates. J Int Neuropsychol Soc 2017; 23(8): 675– 684. doi: 10.1017/ s1355617717000522.

13. Abrahams S, Newton J, Niven E et al. Screening for cognition and behaviour changes in ALS. Amyotroph Lateral Scler Frontotemporal Degener 2014; 15(1– 2): 9– 14. doi: 10.3109/ 21678421.2013.805784.

14. Poletti B, Solca F, Carelli L et al. The validation of the Italian Edinburgh Cognitive and Behavioural ALS Screen (ECAS). Amyotroph Lateral Scler Frontotemporal Degener 2016; 17(7– 8): 489– 498. doi: 10.1080/ 216 78421.2016.1183679.

15. Lule D, Burkhardt C, Abdulla S et al. The Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen: a cross- sectional comparison of established screening tools in a German- Swiss population. Amyotroph Lateral Scler Frontotemporal Degener 2015; 16(1– 2): 16– 23. doi: 10.3109/ 21678421.2014.959451.

16. Niven E, Newton J, Foley J et al. Validation of the Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen (ECAS): a cognitive tool for motor disorders. Amyotroph Lateral Scler Frontotemporal Degener 2015; 16(3– 4): 172– 179. doi: 10.3109/ 21678421.2015.1030430.

17. Bezdicek O, Michalec J, Nikolai T et al. Clinical validity of the Mattis Dementia Rating Scale in differentiating mild cognitive impairment in Parkinson‘s disease and normative data. Dement Geriatr Cogn Disord 2015; 39(5– 6): 303– 311. doi: 10.1159/ 000375365.

18. Bezdicek O, Stepankova H, Martinec Novakova L et al. Toward the processing speed theory of activities of daily living in healthy aging: normative data of the Functional Activities Questionnaire. Aging Clin Exp Res 2016; 28(2): 239– 247. doi: 10.1007/ s40520-015- 0413- 5.

19. Yesavage JA, Sheikh JI. 9/ Geriatric Depression Scale (GDS). Clinical Gerontologist 1986; 5(1– 2): 165– 173. doi: 10.1300/ J018v05n01_09.

20. Kopecek M, Stepankova H, Lukavsky J et al. Montreal cognitive assessment (MoCA): normative data for old and very old Czech adults. Appl Neuropsychol Adult 2017; 24(1): 23– 29. doi: 10.1080/ 23279095.2015.1065261.